CION Ameerpet
If you have typed a stage into a search box and found a percentage, you are holding a number that was never about you. Survival statistics describe large groups of women diagnosed years ago — they cannot tell you what happens next in your own case. This page explains what those figures measure, why the stage-by-stage versions mislead, and which parts of your situation actually shape the outlook.
An ovarian cancer survival rate is a number about a crowd. The figures quoted online are almost always five-year relative survival: of every hundred women diagnosed at a given stage, how many were still alive five years later, compared with women of the same age in the general population. It describes what happened to a group of people who were diagnosed, treated and followed up years ago.
That single sentence carries three quiet limitations. The number is historical. It is an average across women whose disease and treatment differed enormously. And five years is a convention borrowed from cancers that behave nothing like this one — ovarian cancer is frequently a disease of remission, recurrence and further treatment, and being alive at five years says nothing about which of those a woman is living through.
None of this makes the statistics useless. They are how health services are planned and how treatments are compared against each other. They are simply the wrong instrument for the question most people are actually asking, which is what happens to me. That question is answered by your histopathology report, by what the surgery achieved, and by how the disease responds to first-line treatment — not by a table. If you want the staging system itself explained first, start with FIGO staging for ovarian cancer.
A survival figure is the experience of hundreds of women pooled into one number. It tells you about the group. It cannot tell you which part of that group you belong to.
A five-year figure needs five years of follow-up, so it reports treatment given long before current surgical practice and maintenance therapy became routine.
Relative survival adjusts for deaths from other causes by comparing women who have ovarian cancer with women of the same age who do not. It is not a measure of cure.
FIGO revised the staging of ovarian, fallopian tube and peritoneal cancer in 2014, and the revision moved the goalposts. Disease confined to the retroperitoneal lymph nodes became Stage IIIA1; under the earlier system the same woman was Stage IIIC. Stage IV was split into IVA (malignant pleural effusion) and IVB (spread to organs outside the abdomen), and ovarian, fallopian tube and primary peritoneal cancers were brought under a single staging system because they behave as one disease. Survival tables that span the changeover are therefore comparing differently defined groups — one reason stage-by-stage percentages should never be read as precise. Source: Prat J, FIGO Committee on Gynecologic Oncology, International Journal of Gynecology & Obstetrics (2014); WHO Classification of Tumours, Female Genital Tumours (2020).
Every published survival statistic for ovarian cancer carries the same set of distortions. Knowing them is not false hope — it is the difference between reading a number correctly and being frightened by it.
A five-year survival figure can only be calculated once five years have passed, and the datasets behind the published tables usually reach back a good deal further than that. The women counted in them were treated with the surgery and the chemotherapy of that era.
Since those groups were treated, PARP-inhibitor-class maintenance therapy after first-line platinum-based chemotherapy has moved into routine practice for women with BRCA variants and HRD-positive tumours, anti-angiogenic maintenance has established a role, and complete cytoreduction has become the explicit surgical goal rather than an aspiration. A number calculated before those changes cannot account for them.
The largest group in any ovarian cancer table is Stage III, and it covers an enormous range: microscopic peritoneal deposits just beyond the pelvis at one end, extensive disease across the upper abdomen at the other. Both are reported as a single figure.
Under the 2014 FIGO system, Stage IIIA1 means disease found only in retroperitoneal lymph nodes, while Stage IIIC means abdominal deposits larger than two centimetres. They sit in the same row of the same table. If you have been given a substage, that substage carries far more information than the roman numeral — the FIGO stages explained sets out what each one means.
Ovarian cancer is not one disease. High-grade serous carcinoma, the most common form, behaves very differently from low-grade serous, clear cell, mucinous and endometrioid carcinoma, and differently again from germ cell tumours, which typically affect younger women and are usually highly treatable.
Borderline tumours are often pulled into the same public conversation, and they are not invasive cancers at all. A figure that averages all of these together describes none of them accurately. Your histopathology report, not the stage alone, tells you which disease you are dealing with.
The completeness of cytoreductive surgery is the strongest single surgical determinant of how ovarian cancer behaves afterwards, and it is not captured by a stage at all. Two women can share a stage and yet have entirely different amounts of disease remaining in the abdomen when the operation ends.
This is why ovarian cancer surgery belongs with high-volume gynaecologic-oncology teams. CION coordinates debulking and staging surgery with specialist partner centres, where the operation is performed and may be billed — we would rather state that plainly than let it be discovered later.
The most informative prognostic information usually arrives after the statistic has already been read. How completely the disease responds to first-line platinum-based chemotherapy, and how long any remission lasts before recurrence, tells an oncologist more than the stage ever did.
That is why oncologists become more, not less, willing to discuss outlook as treatment progresses. Early on, the honest answer is that the picture is incomplete. There is more on the individual variables in our guide to what affects ovarian cancer prognosis.
Relative survival adjusts for background mortality in the population, but it cannot adjust for how well one woman tolerates surgery and chemotherapy. Age, heart and kidney function, nutrition and muscle mass all shape whether the treatment that was planned can actually be completed.
This is the part of the picture most open to change. Correcting anaemia, protecting nutrition and keeping chemotherapy on schedule at full dose are unglamorous, and they influence the outcome more than most people expect.
None of these is an emergency. Each is a gap worth closing before you let any number settle in your mind, and each is a reasonable thing to ask for — or to seek a second opinion about.
A stage without the histological subtype and grade is half a diagnosis. Ask for the histopathology report and have it explained to you.
Whether any visible disease remained at the end of the operation shapes everything that follows. It should be stated in the operation note, in plain words.
Testing is recommended for every woman with high-grade epithelial ovarian cancer. It changes maintenance treatment, and it matters for your relatives.
A number given without the histopathology report, the operative findings and your treatment response in front of the person saying it is a guess dressed as data.
IIIA1 and IIIC are both Stage III, and they are not the same situation. Ask which one applies to you and why.
Maintenance therapy, the follow-up schedule and what will be monitored belong in the same conversation as the diagnosis, not in a later surprise.
If two or more of these apply, asking for a second opinion is reasonable and offends nobody. Bring the histopathology report, the operation note, your imaging and your chemotherapy records — the consultation is free, and the discussion is far more useful with the paperwork in the room.
Stage and substage, subtype and grade, what the surgery achieved, and what your BRCA and HRD results mean — in one unhurried 45-minute consultation, at no cost. A number from a search result is not a prognosis. Your own file is where the answer starts.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and runs to 45 minutes. We will explain your stage, substage and subtype in plain language, and set out the ovarian cancer treatment options in Hyderabad that apply to your situation.
These are the factors an oncologist weighs when someone asks about ovarian cancer prognosis stage by stage. Some are fixed at diagnosis; others are still very much in play.
| Factor | Why it matters | Still in play? |
|---|---|---|
| FIGO stage and substage | How far the disease had spread when it was found. The substage carries far more information than the roman numeral on its own. | Fixed at diagnosis |
| Residual disease after surgery | Whether visible disease remained when the operation ended is the strongest surgical predictor of what follows. | Decided at surgery — which is why the centre and the surgical team matter |
| Histological subtype and grade | High-grade serous, low-grade serous, clear cell, mucinous and endometrioid carcinomas behave and respond differently. | Fixed, but only known once pathology is complete |
| BRCA and HRD status | Predicts response to platinum-based chemotherapy and decides eligibility for PARP-inhibitor-class maintenance therapy. | Testable now, in-house at CION |
| Response to first-line chemotherapy | How completely the disease responds, and how long remission lasts, outweighs the stage as treatment progresses. | Emerges over the first year |
| Fitness, nutrition and other illnesses | Determine whether the planned treatment can be completed on schedule and at full dose. | Actively modifiable |
*No single row decides anything on its own. Prognosis is a conversation that becomes more accurate as these are known, which is why an honest oncologist's answer changes over the first year rather than staying fixed.
Most people reach a page like this holding a percentage and a diagnosis, with no way of connecting the two. The work of a first consultation is to replace that borrowed number with your own information: what the histopathology says, what the surgery achieved, what the imaging shows, and what has not yet been tested.
The first consultation at CION is free and runs to about 45 minutes. Bring every report you have, including the operation note. Cases are discussed at a tumour board rather than decided by one clinician, and we do not order tests that will not change a decision.
CION delivers medical oncology in-house — platinum-based chemotherapy and maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling, BRCA and HRD testing, nutrition support and long-term survivorship follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and intraperitoneal chemotherapy are coordinated with specialist partner centres and may be billed there. You can see how the whole pathway fits together in our guide to ovarian cancer treatment in Hyderabad, or start from the complete ovarian cancer guide.
Free, unhurried, and long enough to work through a histopathology report properly instead of summarising it in one sentence.
With genetic counselling before and after the test, so the result is understood — by you, and by the relatives it may concern.
Medical oncology, imaging and pathology review the file together rather than one clinician deciding alone. Second opinions are free.
Chemotherapy, maintenance therapy and follow-up delivered close to where you live, rather than requiring repeat trips to one city hospital.
We do not publish stage-by-stage percentages, because for every reason set out on this page they would mislead more than they inform. We publish one figure, always beside the national comparison, so that it can be judged rather than taken on trust.
81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That is one-year survival across the whole treated population. It is not a cure rate, it is not a five-year figure, and it is not a prediction for any individual — your own outlook depends on stage and substage, subtype, what the surgery achieved, and how the disease responds to treatment.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Not a cure rate, and not your prognosis. Survival statistics for ovarian cancer describe groups; only your own file describes you.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data (ICMR / NCRP). Survival statistics describe groups, not individuals — discuss your own outlook with your treating oncologist.
There is no single honest answer, and any page that gives you one is simplifying. Published figures are usually five-year relative survival, calculated from women diagnosed years earlier and averaged across substages, histological subtypes and very different surgical outcomes. They describe a group, not a person. CION publishes one figure it can stand behind: 81.0% of our ovarian cancer patients are alive at one year, against a national figure of 73.7%. That is one-year survival across the whole treated population, not a cure rate and not a prediction for any individual. What shapes your own outlook is the subtype and grade on your histopathology report, how much disease remained after surgery, your BRCA and HRD status, and how the disease responds to first-line platinum-based chemotherapy.
Usually because it is too early for a percentage to mean anything. At diagnosis an oncologist knows the stage and the imaging. What is not yet known is how completely surgery will clear the disease, what the final pathology will show, whether the tumour carries a BRCA variant or is HRD-positive, and how the disease will respond to chemotherapy. Each of those shifts the picture more than the stage does. Anyone quoting a firm percentage on day one is quoting a population average and calling it a prognosis. Ask instead what the plan is, what would change it, and when the picture will be clearer. Those questions have real answers, and the outlook discussion becomes far more useful once first-line treatment is underway.
No. Advanced ovarian cancer is treated with intent, and it frequently responds well: it is among the more chemotherapy-sensitive solid cancers, and long remissions after surgery and platinum-based chemotherapy are common rather than exceptional. Most ovarian cancer is found at an advanced stage, so the whole treatment pathway is built around that reality. What matters within stage III and stage IV is how completely the disease can be cleared surgically, the histological subtype, and whether maintenance therapy is an option once first-line chemotherapy finishes. None of that is settled by the roman numeral. It is also worth knowing that stage III spans a very wide range, from lymph-node-only involvement to extensive abdominal deposits, so the substage is the more informative number to ask about.
Counter-intuitively, women with a BRCA1 or BRCA2 pathogenic variant tend to respond better to platinum-based chemotherapy than women without one, and they are the group in whom PARP-inhibitor-class maintenance therapy has shown the clearest benefit. The same applies, to a lesser degree, to tumours that are HRD-positive without an inherited BRCA variant. So the test is not only about family risk: it directly shapes what treatment is offered after first-line chemotherapy. Testing is recommended for every woman diagnosed with high-grade epithelial ovarian cancer, and it is done in-house at CION with genetic counselling before and after the result. If a variant is found, blood relatives can be tested, which is where the finding begins to protect other people in your family.
No, and this is where five-year figures cause the most confusion. Five-year survival simply counts who is alive at five years. Ovarian cancer often behaves as a disease of remission and recurrence, so a woman can be alive at five years while in remission, while on treatment, or having finished treatment entirely, and the statistic does not distinguish between them. Equally, being in remission at two years is not a guarantee that it will hold. Oncologists therefore talk about remission, and about the interval before any recurrence, rather than about cure, particularly in the early years. That is not evasiveness. It is a more accurate description of how this disease behaves, and it leaves room for the fact that recurrence, when it happens, is itself treatable.
Not in any useful way. Published stage-based figures are calculated from the point of first diagnosis, so they were never designed to answer questions about recurrent disease. Once ovarian cancer recurs, different questions guide treatment: how long the interval was between finishing platinum-based chemotherapy and the recurrence, where the disease has returned, how well you tolerated previous treatment, and what has already been used. That interval in particular strongly influences which treatments are likely to work next. Recurrent ovarian cancer is treated, often over a long period and often with good control of symptoms, and decisions are made case by case rather than read off a table.
The first consultation is free and runs to about 45 minutes, and it is worth bringing every report you have. CION delivers medical oncology for ovarian cancer in-house: platinum-based chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and intraperitoneal chemotherapy are coordinated with specialist partner centres, where they are performed and may be billed, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board rather than decided by one doctor, and second opinions are free. Aarogyasri, CGHS and cashless insurance are accepted.